Xenetic Biosciences(XBIO) - 2025 Q1 - Quarterly Results

Form 8-K Filing Information This section details the registrant's identification, incorporation, SEC filing particulars, and registered securities information Registrant and Filing Details This section identifies Xenetic Biosciences, Inc. as the registrant, detailing its incorporation, SEC file number, and the Form 8-K filing date - Registrant: Xenetic Biosciences, Inc.[2] - Date of Report: May 14, 2025[2] - State of Incorporation: Nevada[2] - Commission File Number: 001-37937[2] Securities Information This section details the company's registered securities, including Common Stock on Nasdaq, and confirms its non-emerging growth status Registered Securities | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock, $0.001 par value per share | XBIO | The Nasdaq Stock Market | - Registrant is not an emerging growth company[4] Item 2.02 Results of Operations and Financial Condition This section details the announcement of Xenetic Biosciences, Inc.'s Q1 2025 financial results via a press release, furnished as Exhibit 99.1 Q1 2025 Financial Results Announcement Xenetic Biosciences, Inc. announced Q1 2025 financial results via a May 14, 2025 press release, furnished as Exhibit 99.1, not deemed "filed" for Section 18 purposes - Company issued a press release on May 14, 2025, announcing results for the three months ended March 31, 2025[6] - The press release is furnished as Exhibit 99.1 to this Form 8-K and incorporated by reference[7] - Information in Item 2.02, including Exhibit 99.1, is not deemed 'filed' for Section 18 of the Securities Exchange Act of 1934 purposes[7] Forward-Looking Statements This section provides a disclaimer for forward-looking statements, highlighting inherent risks and the company's limited obligation to update them Disclaimer on Future Projections This disclaimer states that Form 8-K contains forward-looking statements subject to safe harbor provisions, based on current expectations, and involve risks - This Form 8-K contains forward-looking statements subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995[8] - Forward-looking statements are based on current expectations and involve risks and uncertainties, as detailed in the Company's SEC reports[8] - The Company does not undertake to update forward-looking statements, except as required by law[8] Item 9.01 Financial Statements and Exhibits This section provides a comprehensive list of exhibits accompanying the Form 8-K, including the Q1 2025 financial results press release Exhibits List This section lists the Form 8-K exhibits, including the Q1 2025 financial results press release (Exhibit 99.1) and the Cover Page Interactive Data File (Exhibit 104) Form 8-K Exhibits | Exhibit No. | Description | | --- | --- | | 99.1 | Press Release dated May 14, 2025 pertaining to the financial results of the Company for the three months ended March 31, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | Signatures This section confirms the authorized signing of the Form 8-K by the Interim Chief Executive Officer & Chief Financial Officer Authorized Signatory The report was duly signed by James Parslow, Interim CEO & CFO, on May 14, 2025, as per Securities Exchange Act of 1934 requirements - Report signed by James Parslow, Interim Chief Executive Officer & Chief Financial Officer[12] - Date of signature: May 14, 2025[12] - Signing pursuant to the requirements of the Securities Exchange Act of 1934[11]